Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars
Primary Purpose
Scars, Insulin
Status
Recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Microneedling with topical application of regular insulin
Microneedling with topical application of saline
Sponsored by
About this trial
This is an interventional treatment trial for Scars focused on measuring Insulin, scars
Eligibility Criteria
Inclusion Criteria: Patients aged 12 to 60 years Atrophic scars (traumatic or surgical) Completely healed scars Exclusion Criteria: Patients with a tendency or history of hypertrophic or keloidal scars Patients who received treatment for their scar in the past 3 months Diabetic patients or those with a history of Dysglycemia Pregnant, or lactating females Patients with active infection at the site of scar Patients currently receiving isotretinoin treatment or in the past month
Sites / Locations
- Alexandria University, Faculty of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Microneedling with topical application of regular insulin
Microneedling only
Arm Description
Outcomes
Primary Outcome Measures
Change in Scar
According the different scar assessment scores (e.g.POSAS score - The Patient and Observer Scar Assessment Scale score, range from 6 to 60, the higher the score the worse the scar, lowering in the score denotes improvement )
Secondary Outcome Measures
Full Information
NCT ID
NCT06021275
First Posted
August 27, 2023
Last Updated
September 7, 2023
Sponsor
Alexandria University
1. Study Identification
Unique Protocol Identification Number
NCT06021275
Brief Title
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars
Official Title
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Alexandria University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scars, Insulin
Keywords
Insulin, scars
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Microneedling with topical application of regular insulin
Arm Type
Active Comparator
Arm Title
Microneedling only
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
Microneedling with topical application of regular insulin
Intervention Description
Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
Intervention Type
Other
Intervention Name(s)
Microneedling with topical application of saline
Intervention Description
Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
Primary Outcome Measure Information:
Title
Change in Scar
Description
According the different scar assessment scores (e.g.POSAS score - The Patient and Observer Scar Assessment Scale score, range from 6 to 60, the higher the score the worse the scar, lowering in the score denotes improvement )
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged 12 to 60 years
Atrophic scars (traumatic or surgical)
Completely healed scars
Exclusion Criteria:
Patients with a tendency or history of hypertrophic or keloidal scars
Patients who received treatment for their scar in the past 3 months
Diabetic patients or those with a history of Dysglycemia
Pregnant, or lactating females
Patients with active infection at the site of scar
Patients currently receiving isotretinoin treatment or in the past month
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dalia I Halwag, PhD, MD
Phone
+00201224489473
Email
daliahalwag@gmail.com
Facility Information:
Facility Name
Alexandria University, Faculty of Medicine
City
Alexandria
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dalia I Halwag, PhD, MD
Phone
+0201224489473
Email
daliahalwag@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Study protocol after finishing all the research and publishing the research
Learn more about this trial
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars
We'll reach out to this number within 24 hrs